Welcome to LookChem.com Sign In|Join Free
  • or
sodium 4-chlorobenzylidenepyruvate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

222052-48-4

Post Buying Request

222052-48-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

222052-48-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 222052-48-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,2,0,5 and 2 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 222052-48:
(8*2)+(7*2)+(6*2)+(5*0)+(4*5)+(3*2)+(2*4)+(1*8)=84
84 % 10 = 4
So 222052-48-4 is a valid CAS Registry Number.

222052-48-4Relevant academic research and scientific papers

SUBSTITUTED PYRIDINE COMPOUNDS AS PESTICIDES

-

Paragraph 0489-0490, (2019/02/28)

The present invention relates to novel substituted pyridine compounds of the formula (I) in which R1, R2, R3, R4, R5, R6, V1, V2 and Q1 have the definitions

Substituted pyrazoline for preventing weight gain

-

Page/Page column 92; 116-117, (2008/12/07)

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one drug, known to produce weight-gain as a side effect, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.

Combination of substituted pyrazolines and agent for treating dyslipidemia

-

Page/Page column 32, (2008/12/07)

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one lipid lowering compound used to treat dyslipidaemia, a medicament comprising said active substance combination, a pha

A-polymorph of a substituted pyrazoline, its preparation and use as medicaments

-

Page/Page column 16, (2008/12/07)

The present invention relates to the α-Polymorph of (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide, methods for its preparation, medicaments comprising this compound as well as their use for the prepara

SALTS OF SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS

-

Page/Page column 81-82, (2008/06/13)

The present invention relates to salts of substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

Combination of a substituted pyrazoline compound and a drug used in food-related disorders

-

Page/Page column 22, (2008/06/13)

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one compound used in food-related disorders, a medicament comprising said active substance combination, a pharmaceutical

Combination of pyrazoline type cannabinoid receptor antagonist and statin

-

Page/Page column 22-23, (2008/06/13)

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one statin compound, a medicament comprising said active substance combination, a pharmaceutical formulation comprising s

Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome

-

Page/Page column 18, (2008/06/13)

The present invention relates to the use of substituted pyrazoline compounds for the manufacture of a medicament for the treatment of metabolic syndrome.

ACTIVE SUBSTANCE COMBINATION

-

Page/Page column 44, (2008/06/13)

The present invention relates to an active substance combination comprising at least one substituted pyrazoline compound and at least one anti-addictive compound, a medicament comprising said active substance combination, a pharmaceutical formulation comp

CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression

-

Page/Page column 22, (2008/06/13)

The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 222052-48-4